Inhibrx Biosciences to Present Research at Multiple Scientific Conferences in 2026

SAN DIEGO, Oct. 13, 2026 /CourierPR/ -- Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, will present its research at several upcoming scientific conferences in 2026.

At the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, on October 25th, 2026, the company will present the phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) in combination with pembrolizumab as first-line treatment (1L tx) of PD-L1, high recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The presentation will be an oral presentation led by Jong Chul Park, scheduled for Sunday, October 25th, 2026, from 8:30 to 10:00 AM Central European Time (CET).

In Miami, Florida, at the 2026 Musculoskeletal Tumor Society (MSTS) Annual Meeting on October 29th, 2026, Inhibrx Biosciences will present the secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study of the tetravalent Death Receptor 5 (DR5) agonist Ozekibart (INBRX-109) in conventional chondrosarcoma. The presentation will be an oral presentation led by Robin Jones, scheduled for Thursday, October 29th, 2026, from 2:50 to 3:40 PM Eastern Standard Time (EST).

At the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting in Seoul, South Korea, on November 19th and 20th, 2026, Inhibrx Biosciences will present two oral presentations. The first, on Friday, November 20th, 2026, from 11:00 AM to 12:30 PM Korea Standard Time (KST), will focus on the subgroup analysis and updated progression-free survival (PFS) from the randomized, phase 2 ChonDRAgon study of the tetravalent Death Receptor 5 (DR5) agonist Ozekibart (INBRX-109) in conventional chondrosarcoma. The second presentation, on Thursday, November 19th, 2026, from 5:30 to 6:30 PM KST, will be a poster presentation on the phase 1/2 study of the tetravalent Death Receptor 5 (DR5) agonist Ozekibart (INBRX-109) combined with irinotecan (I) and temozolomide (T) in adolescents and adults with Ewing sarcoma. This presentation will be led by Varun Monga.

Inhibrx Biosciences, Inc., was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following these transactions, Inhibrx Biosciences' current clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and ordastobart (INBRX-106), both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what the company believes to be the most appropriate agonist function.